COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination with Rituximab in Subjects with Treatment Naïve Marginal Zone Lymphoma

Protocol No
MSKCC-19-243-MZL
Principal Investigator
Timothy Fenske
Phase
III
Summary
The purpose of this study is to see if the combination of Rituximab and Ibrutinib can help people with Marginal Zone Lymphoma who have not received treatment in the past. The study will also compare the combination of Rituximab and Ibrutinib with the combination of Rituximab and placebo to see which combination works better. In addition, the study will look at the safety of both combinations.
Description
Ibrutinib With Rituximab in Untreated Marginal Zone Lymphoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL